关于管理晚期前列腺癌的跨学科瑞士共识建议.
Arnoud J Templeton1,2, Vérane Achard3, Dilara Akhoundova4
1Medical Oncology, St. Claraspital, Basel, Switzerland, St. Clara Research Ltd., Basel, Switzerland, and Faculty of Medicine, University of Basel, Basel, Switzerland.
Praxis
|May 28, 2025
概括
本研究介绍了瑞士专家小组对晚期前列腺癌诊断和治疗的投票结果. 其目的是协调当地高级和转移性前列腺癌护理的国家实践.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 最近在局部晚期和转移性前列腺癌诊断和治疗方面的进展.
- 需要最新的患者咨询和治疗建议.
- 由于模两可的情况和不同的治疗选择,日常实践中的挑战.
研究的目的:
- 介绍瑞士专家小组关于前列腺癌管理的投票结果.
- 在全国范围内协调局部晚期和转移性前列腺癌的诊断和治疗.
- 为患者和医生讨论前列腺癌护理提供基础.
主要方法:
- 2024年8月召开瑞士专家小组会议.
- 在高级前列腺癌会议 (2024年4月) 中,国际专家小组讨论了选定的问题.
- 专家小组投票结果的收集和呈现.
主要成果:
- 来自瑞士专家的投票结果关于前列腺癌诊断和治疗的关键方面.
- 确定需要国家协调的前列腺癌护理领域.
- 对管理晚期前列腺癌的专家共识的洞察.
结论:
- 提交的投票结果旨在促进国家对前列腺癌诊断和治疗的协调.
- 这种协调将支持基于证据的决策,用于局部晚期和转移性前列腺癌.
- 这些发现为改善患者咨询和治疗计划提供了基础.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Acute Coronary Syndrome IV: Interprofessional Care
32
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
32
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Urinary Tract Calculi III: Medical Management
32
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
32
Aneurysm III: Interprofessional Care
30
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
30
Peripheral Artery Disease III: Interprofessional Care
35
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
35


